April 11, 2022
Patients with resectable gastric and gastroesophageal junction adenocarcinoma experienced good pathologic complete response with standard of care chemotherapy and perioperative/adjuvant pembrolizumab.
April 11, 2022
Patients with advanced or metastatic endometrial cancer experienced a significant non-progression rate following treatment with olaparib, metronomic cyclophosphamide, and metformin.
March 19, 2022
The ongoing KEYNOTE-B21 trial aims to determine if pembrolizumab plus adjuvant chemotherapy with or without radiotherapy will improve disease-free survival and overall survival in patients with newly diagnosed endometrial cancer.
February 20, 2022
Better health-related quality of life outcomes were associated with nivolumab and cabozantinib for advanced renal cell carcinoma vs sunitinib.
September 19, 2021
Data from the phase 3 DESTINY-Breast03 trial show trastuzumab deruxtecan bests trastuzumab emtansine in patients with previously treated HER2-positive metastatic breast cancer.
September 08, 2021
Patients with stage IIIB and stage IV advanced squamous non–small cell lung cancer experienced a clinically significant improvement in progression-free survival with tislelizumab plus chemotherapy in the first-line setting compared with standard of care chemotherapy.